Oral and vaginal administration: Severe liver disease (if the results of liver function tests have failed to return to normal), hepatic cell tumors, rotor syndrome and Dubin-Johnson syndrome; Hypersensitivity to progesterone or to any of the excipients; Thrombophlebitis, thromboembolic disorders, cerebral hemorrhage, or history of these conditions; Carcinoma of the breasts; Suspected or confirmed breast or genital organ neoplasia; Undiagnosed vaginal bleeding.